Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

Callander, Natalie S.; Comenzo, Raymond L.; Cornell, Robert F.; Costa, Luciano J.; D'Souza, Anita; Dispenzieri, Angela; Freytes, César O.; Ganguly, Siddhartha; Gertz, Morie A.; Hari, Parameswaran; Huang, Jiaxing; Kamble, Rammurti T.; Kindwall-Keller, Tamila L.; Kumar, Shaji; Kyle, Robert A.; Landau, Heather J.; Lazarus, Hillard M.; Mark, Tomer M.; Moreb, Jan S.; Nishihori, Taiga; Olsson, Richard F.; Peter Gale, Robert; Ramanathan, Muthalagu; Savani, Bipin N.; Scott, Emma C.; Vogl, Dan T.; Weiss, Brendan M.; Wirk, Baldeep; Wood, William A.; Zhang, Mei-Jie

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

Abstract

Autologous hematopoietic cell transplantation, or autotransplantation, is effective in light-chain amyloidosis (AL), but it is associated with a high risk of early mortality (EM). In a multicenter randomized comparison against oral chemotherapy, autotransplantation was associated with 24% EM. We analyzed trends in outcomes after autologous hematopoietic cell transplantation for AL in North America

Similar works

Full text

Open in the Core reader

Download PDF

Available Versions

Carolina Digital Repository

cdr.lib.unc.edu:vm40z0281

Last time updated on 24/11/2020